Summary:

«Around the world, the burden of chronic disease is increasing at a rapid pace. Unfortunately, most of these conditions are irreversible and need to be managed through lifelong medication use. However, many patients struggle with adhering to prescribed medications and implementing the behavioral and lifestyle changes that are needed to manage their diseases and stabilize their conditions. Often, physicians and other healthcare providers have little ability to monitor the extent to which patients are following their recommendations and maintaining treatment regimens. As a result, disease burdens at a population level are higher than they should be.»

«The impact potential here is significant, both in terms of clinical outcomes and economic benefits for stakeholders and societies. For example, research has shown that digital disease management can drive a 45 percent reduction in the three-month rate of major adverse cardiovascular events (MACEs) and a 50 percent reduction in the 30-day readmission rates for patients after acute myocardial infarction (AMI). Similarly, it can help lower hemoglobin A1c (HbA1c) levels by one percentage point among patients with type 2 diabetes. These data points illustrate the extent to which digital disease manage­ment can help save lives while also keeping patients healthier, which reduces costs for many stake­holders, including the patients themselves.»

Article written by Chirag Adatia, Ralf Dreischmeier, Samarth Shah, and Kirtika Sharma

27|01|2023

Source:

Mckinsey

https://www.mckinsey.com/industries/life-sciences/our-insights/the-health-benefits-and-business-potential-of-digital-therapeutics